View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 18, 2022

Innovent reports positive data from two Phase III hypercholesterolemia trials

An immunoglobulin G2 (IgG2) fully human monoclonal antibody, IBI306 attaches to PCSK9. 

Innovent Biologics has reported that two Phase III clinical trials, CREDIT-1 and CREDIT-4, analysing its antibody IBI306 for hypercholesterolemia met the primary endpoint. 

The company expects to submit a new drug application (NDA) for IBI306 in China to treat individuals with primary hypercholesterolemia and combined hyperlipidemia.

The double-blind, randomised, placebo-controlled CREDIT-1 trial analysed the safety and efficacy of IBI306 in non-familial hypercholesterolemia (non-FH) patients with high/very high cardiovascular risk in China. 

The percentage decline from baseline in low-density lipoprotein cholesterol (LDL-C) following treatment for 48 weeks was the primary efficacy goal of this trial.

The randomised, double-blind, placebo-controlled CREDIT-4 trial also evaluated the safety and efficacy of IBI306 in individuals with hypercholesterolemia including non-FH and heterozygous familial hypercholesterolemia (HeFH) in China.

For this trial, the percentage decline in LDL-C from baseline following treatment for 12 weeks was the primary efficacy goal.

Results from both the trials showed that the LDL-C levels in the control arm were substantially lower as against the placebo arm. 

Furthermore, IBI306 was found to have a good safety profile in the trials, in line with those of other PCSK-9 inhibitors marketed currently.

An immunoglobulin G2 (IgG2) fully human monoclonal antibody, IBI306 attaches to proprotein convertase subtilisin/kexin type 9 (PCSK9). 

It thereby lowers the levels of LDL-C by hindering low-density lipoprotein receptor (LDLR) endocytosis mediated by PCSK-9.

This approach boosts LDL-C clearance causing a drop in the level of LDL-C.

Innovent executive director Dr Lei Qian said: “The results of these two clinical studies, CREDIT-1 and CREDIT-4, further confirmed the clinical significance of IBI306 in the treatment of patients with different types of hypercholesterolemia in China. 

“With the successive completion of various clinical studies, it is expected to propose a new drug application for IBI306 this year.”

In August last year, Innovent reported that IBI306 met the primary goal of the Phase III CREDIT-2 trial in HeFH patients in China.

Related Companies

Free Whitepaper

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy